Jechobio Receives NMPA IND Clearance for JLM019 for the Treatment of Advanced Malignant Tumors

August 21, 2025 Tianjin, China - Jecho Biopharmaceuticals Co., Ltd. (hereinafter referred to as “Jechobio”), a global, clinical stage biopharmaceutical company advancing medicines focusing in oncology, today announced that the…

Continue ReadingJechobio Receives NMPA IND Clearance for JLM019 for the Treatment of Advanced Malignant Tumors

Inside Precision Medicine highlights GPC3-targeting imaging agent to improve liver cancer detection 

June 25, 2025  Inside Precision Medicine highlights GPC3-targeting imaging agent to improve liver cancer detection  A recent article highlights the clinical results from a GPC3-targeting agent, 68Ga-a-GPC3-scF, which was shown…

Continue ReadingInside Precision Medicine highlights GPC3-targeting imaging agent to improve liver cancer detection 

Jechobio Collaborates with Industry Peers to Announce Promising Clinical Data for Innovative GPC3-Targeted Radionuclide Drug

21 April, 2025 – Jecho Biopharmaceuticals Co., Ltd. (hereinafter referred to as "Jechobio"), in collaboration with Wuhan Raydif Biotechnology Co., Ltd. (hereinafter referred to as "Raydif"), and Grand Pharmaceutical Group…

Continue ReadingJechobio Collaborates with Industry Peers to Announce Promising Clinical Data for Innovative GPC3-Targeted Radionuclide Drug